Current Version
| Region | New Zealand |
| Issue | Gender-affirming care |
| Status | Legal |
| Start Date | (unknown) |
| End Date | (none) |
| Description | Informed consent for HRT was adopted nationwide during 2023 as according to the Primary Care Gender Affirming Hormone Therapy Initiation Guidelines (2023 - Aotearoa New Zealand). This guides GPs on how to initiate GAHT and has been adopted by many GPs. It should be noted that some GPs may not follow these guidelines completely. Access to Puberty Blockers for minors under 16 whilst still not restricted sees further scrutiny as of late 2024 with the following position "Noting that the Government has signalled an intent to consider regulating puberty blocker prescribing in gender-affirming care, clinicians should exercise caution in prescribing. Clinicians who initiate puberty blockers should be experienced in providing gender-affirming care and be part of an interprofessional team offering a full range of supports to young people presenting with gender-related issues." |
| Sources | https://www.health.govt.nz/publications/position-statement-on-the-use-of-puberty-blockers-in-gender-affirming-care https://patha.nz/Guidelines |
| Federal Law | Yes |
👍 NEW: Helpful votes! You can now rate each edit as helpful or unhelpful. Votes add another layer of approval and are an easy way to say thank you to other editors. Helpful votes may become public in the future but unhelpful votes will always remain private.
Revision History (2)
| Old Value (Original) | New Value (Current) | |
|---|---|---|
| Description | Informed consent for HRT was adopted by the nationwide during 2023 as acording to the Primary Care Gender Affirming Hormone Therapy Initiation Guidelines (2023 - Aotearoa New Zealand). This guides GPs on how to initiate GAHT and has been adopted by many GPs. It should be noted that some GPs may not follow these guidelines completely. Access to Puberty Blockers for minors under 16 whilst still not restricted sees further scrutiny as of late 2024 with the following position "Noting that the Government has signalled an intent to consider regulating puberty blocker prescribing in gender-affirming care, clinicians should exercise caution in prescribing. Clinicians who initiate puberty blockers should be experienced in providing gender-affirming care and be part of an interprofessional team offering a full range of supports to young people presenting with gender-related issues." | Informed consent for HRT was adopted nationwide during 2023 as according to the Primary Care Gender Affirming Hormone Therapy Initiation Guidelines (2023 - Aotearoa New Zealand). This guides GPs on how to initiate GAHT and has been adopted by many GPs. It should be noted that some GPs may not follow these guidelines completely. Access to Puberty Blockers for minors under 16 whilst still not restricted sees further scrutiny as of late 2024 with the following position "Noting that the Government has signalled an intent to consider regulating puberty blocker prescribing in gender-affirming care, clinicians should exercise caution in prescribing. Clinicians who initiate puberty blockers should be experienced in providing gender-affirming care and be part of an interprofessional team offering a full range of supports to young people presenting with gender-related issues." |
Show Difference | ||
| Original entry | |
|---|---|
| Status | Legal |
| Federal Law | Yes |
| Start Date | (unknown) |
| End Date | (none) |
| Description | Informed consent for HRT was adopted by the nationwide during 2023 as acording to the Primary Care Gender Affirming Hormone Therapy Initiation Guidelines (2023 - Aotearoa New Zealand). This guides GPs on how to initiate GAHT and has been adopted by many GPs. It should be noted that some GPs may not follow these guidelines completely. Access to Puberty Blockers for minors under 16 whilst still not restricted sees further scrutiny as of late 2024 with the following position "Noting that the Government has signalled an intent to consider regulating puberty blocker prescribing in gender-affirming care, clinicians should exercise caution in prescribing. Clinicians who initiate puberty blockers should be experienced in providing gender-affirming care and be part of an interprofessional team offering a full range of supports to young people presenting with gender-related issues." |
| Sources | https://www.health.govt.nz/publications/position-statement-on-the-use-of-puberty-blockers-in-gender-affirming-care https://patha.nz/Guidelines |